
    
      The purpose of this study is to assess whether the combination of eflornithine 500 mg and
      sulindac 150 mg (compared to corresponding placebos) has efficacy against colorectal lesions
      with respect to high-grade dysplasia, adenomas with villous features, adenomas 1 cm or
      greater, multiple adenomas, any adenomas >/= 0.3 cm, total advanced colorectal events, or
      total colorectal events.
    
  